QNTM Market Analysis
News & Sentiment
49 articles · sorted by dateVia 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
Fundamentals
Updated daily after market closeValuation
- Forward P/E
- —
- PEG ratio
- —
- P/B
- —
- P/S (TTM)
- 91.86
- EV/EBITDA
- -1.57
Profitability & growth
- ROE (TTM)
- -621.0%
- Operating margin
- 0.0%
- Revenue growth YoY
- 0.0%
- Dividend yield
- —
- Beta
- 0.43
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
About Quantum BioPharma Ltd.
Company profileQuantum BioPharma Ltd. (QNTM) is an innovative biotechnology company focused on advancing transformative therapies for oncology and autoimmune diseases. With a robust pipeline of biopharmaceutical products, QNTM is committed to utilizing cutting-edge research and development to address critical unmet medical needs in these therapeutic areas. The company's strategic partnerships and experienced leadership position it to successfully navigate the complexities of the biopharmaceutical landscape. As the demand for groundbreaking therapeutics rises, Quantum BioPharma presents a strong investment…
Classification
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Country
- USA
- Currency
- USD
Company profile
- HQ
- 1 ADELAIDE STREET EAST, TORONTO, ON
- Fiscal year end
- December
- Latest quarter
- Jun 30, 2026
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer
